内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

J CLIN ENDOCR METAB：糖尿病并发症指向上升的痴呆风险

2015-07-14 佚名 生物谷

糖尿病并发症痴呆
关注

根据发表在The Journal of Clinical Endocrinology & Metabolism的一篇研究，患有糖尿病和诸多糖尿病并发症的患者在老年时期更容易患痴呆症，相比于并发症较少的糖尿病患者。 糖尿病患者胰腺不能产生足够胰岛素，或身体不能有效率地利用胰岛素处理多余的糖。如果糖尿病未能控制，血糖长期处于高水平状态下，会发生严重的并发症，包括失明，肾功能衰竭，四肢血流减少

根据发表在The Journal of Clinical Endocrinology & Metabolism的一篇研究，患有糖尿病和诸多糖尿病并发症的患者在老年时期更容易患痴呆症，相比于并发症较少的糖尿病患者。

糖尿病患者胰腺不能产生足够胰岛素，或身体不能有效率地利用胰岛素处理多余的糖。如果糖尿病未能控制，血糖长期处于高水平状态下，会发生严重的并发症，包括失明，肾功能衰竭，四肢血流减少甚至截肢。美国有超过29万人患有糖尿病。而每100位糖尿病患者中，21位有神经损伤，27位有糖尿病肾病，29至33人患有糖尿病视网膜病变。

国立台湾大学公共卫生学院的Wei-Che Chiu教授领导他的团队进行了第一个全国性的研究，探讨糖尿病的轻重和进展与老年痴呆症诊断率之间的关联。

在长达12年之久的人群队列研究中，研究人员使用了台湾全民健康保险研究资料库的记录，从1999年记录开始，找到431178位年龄50岁以上，新诊断的糖尿病患者。研究人员统计分析记录，确认有多少人在被诊断之后送往医院或至少有三个痴呆症门诊记录。为了评估每个人的糖尿病的进展，研究人员使用了糖尿病并发症的严重程度指数（aDCSI），用于预测糖尿病人的死亡率和住院率。

在队列中，共有26856人（6.2％）的患者被诊断为老年痴呆症。糖尿病并发症严重指数高的患者患痴呆症的风险也明显较高。指数评分为1，2，3和大于3的患者换痴呆症的风险分别是1.04，1.40，1.54和1.7 (P<0.001).

这项研究表明糖尿病患者的血糖控制为何如此重要。及时控制血糖发展和糖尿病进程可能有助于防止未来生活中痴呆症的发作。

原始出处

Chiu WC1, Ho WC1, Liao DL1, Lin MH1, Chiu CC1, Su YP1, Chen PC1.Progress of Diabetic Severity and Risk of Dementia.J Clin Endocrinol Metab. 2015 Jul

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895813, encodeId=a859189581383, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Apr 14 02:06:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887447, encodeId=c6e1188e447bf, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 21:06:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35067, encodeId=ec4d3506e14, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:03:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757660, encodeId=53c61e57660ef, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Dec 08 16:06:00 CST 2015, time=2015-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316667, encodeId=3e97131666edd, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413015, encodeId=e0cd1413015a6, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=)]
    2016-04-14 一闲

    #MET#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1895813, encodeId=a859189581383, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Apr 14 02:06:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887447, encodeId=c6e1188e447bf, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 21:06:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35067, encodeId=ec4d3506e14, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:03:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757660, encodeId=53c61e57660ef, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Dec 08 16:06:00 CST 2015, time=2015-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316667, encodeId=3e97131666edd, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413015, encodeId=e0cd1413015a6, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=)]
    2015-08-14 guojianrong

    #Meta#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1895813, encodeId=a859189581383, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Apr 14 02:06:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887447, encodeId=c6e1188e447bf, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 21:06:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35067, encodeId=ec4d3506e14, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:03:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757660, encodeId=53c61e57660ef, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Dec 08 16:06:00 CST 2015, time=2015-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316667, encodeId=3e97131666edd, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413015, encodeId=e0cd1413015a6, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    期待有更多研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1895813, encodeId=a859189581383, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Apr 14 02:06:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887447, encodeId=c6e1188e447bf, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 21:06:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35067, encodeId=ec4d3506e14, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:03:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757660, encodeId=53c61e57660ef, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Dec 08 16:06:00 CST 2015, time=2015-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316667, encodeId=3e97131666edd, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413015, encodeId=e0cd1413015a6, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=)]
    2015-12-08 丁鹏鹏

    #并发#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1895813, encodeId=a859189581383, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Apr 14 02:06:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887447, encodeId=c6e1188e447bf, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 21:06:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35067, encodeId=ec4d3506e14, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:03:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757660, encodeId=53c61e57660ef, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Dec 08 16:06:00 CST 2015, time=2015-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316667, encodeId=3e97131666edd, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413015, encodeId=e0cd1413015a6, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=)]
    2015-07-16 pcw106

    #痴呆风险#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1895813, encodeId=a859189581383, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Apr 14 02:06:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887447, encodeId=c6e1188e447bf, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 21:06:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35067, encodeId=ec4d3506e14, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:03:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757660, encodeId=53c61e57660ef, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Dec 08 16:06:00 CST 2015, time=2015-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316667, encodeId=3e97131666edd, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413015, encodeId=e0cd1413015a6, content=<a href='/topic/show?id=315de670091' target=_blank style='color:#2F92EE;'>#糖尿病并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76700, encryptionId=315de670091, topicName=糖尿病并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6712920539, createdName=axin010, createdTime=Thu Jul 16 05:06:00 CST 2015, time=2015-07-16, status=1, ipAttribution=)]
    2015-07-16 axin010

    #糖尿病并发症#

    0

相关资讯

J Dent Res：糖尿病与骨坏死之间的那些事儿

20世纪初期，Marx 和Ruggiero团队首次报道了颌面部静脉注射双磷酸盐类（BPs）造成伤口未愈合骨暴露的案例。大量的研究表明颌骨骨坏死（MRONJ）与药物的使用有关，主要与BP有关。在抗骨吸收患者中，骨坏死的累积发病率达0.7%至18%。最近的抗骨吸收治疗，包括抑制核因子-κB受体活化因子及其配体以及抗血管生成疗法，这些都与MRONJ发生率的升高有关。BP以及其他的抗骨吸收治疗被认为是MR

Angeles Hospital 的医生采用免疫治疗法避免糖尿病并发症

糖尿病免疫疗法和传统疗法的区别在哪？患者确诊后并得到重视，但也需要检查系统的免疫问题从而阻止可能产生的并发症，包括糖尿病足、青光眼、肾病和视网膜病。墨西哥城Angeles Hospital高级免疫中心内分泌科主任Sigfrido Miracle Lopez说：由于患者具有免疫缺陷（防御功能降低）更容易受到感染，只要免疫问题不能得到治疗那么糖尿病也不能得到完全控制。他进一步解释说：1型糖尿病患者的胰

专家综述：糖尿病的急症管理

　　本文简介：糖尿病是一种常见的疾病。糖尿病患者，尤其是那些社会经济地位较低或很少就机会获得初级健康护理的患者，经常会因急症出现在医院急诊部。因此，本文旨在回顾急诊室中最常见的、危及生命的糖尿病并发症： 糖尿病酮症酸中毒(DKA)，高渗性高血糖状态(HHS)和低血糖。另外， 本文还给出了非糖尿病患者出现高血糖的评估方法。非常值得糖尿病医师和急诊科医师阅读。 　　高血糖危象：DKA和